Advertisement
News
Advertisement

Dr. Reddy’s Announces the Approval of Azacitidine for Injection

Tue, 09/17/2013 - 8:10am

Dr. Reddy’s Laboratories announced today that Azacitidine for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA ® (azacitidine for injection), is approved by the United States Food & Drug Administration (USFDA) on September 16, 2013. The launch of product in the market is planned in the near-term.

The VIDAZA ® brand had U.S. sales of approximately $378.5 Million for the most recent twelve months ending July 2013 according to IMS Health.

Dr. Reddy’s Azacitidine for Injection 100 mg/vial is available in single-use vials.

Advertisement
Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading